Yi Lin
@YiLinMDPhD
Followers
2K
Following
7K
Media
298
Statuses
1K
Professor; Mayo Clinic Comprehensive Cancer Center Deputy Director, Cancer Regenerative Biotherapeutics; Co-Chair, Experimental & Novel Therapeutics DG.
Mayo Clinic, Rochester, MN
Joined April 2013
Trials like AQUILA are great examples to study the design, conduct, and interpretation of randomized trials. #MedTwitter You may see experts argue about how to interpret the trial and what level of benefit will justify practice change. Thats a good thing. But whatever the case
nejm.org
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a...
2
9
80
CAR-T/ immune effector enterocolitis at #ACG2025 and the Mayo Cell Therapy & BMT Conference — a reminder that advancing immunotherapy means understanding its GI toxicities too. #MayoClinic #ImmunoTox @MayoClinicGIHep @YiLinMDPhD
0
2
11
2nd Annual Kyle Barlogie Plasma Cell Disorders Symposium kicks off with session on AL amyloidosis @Taxkourel @MyelomaDrKapoor @ADispenzieri Dr. Heather Landau @mskcc @szusmani @MayoCancerCare @myelomaMD
0
1
15
Beautiful MN fall day to get to Kyle Barlogie Symposium in Plasma Cell Disorders! @MayoCancerCare @SocietyofMSKCC
https://t.co/RmMxFMjsVP
0
1
12
Inspiring lecture by @Leif_Bergsagel @MayoClinic after receiving the Ken Anderson Award at #IMS25 @Myeloma_Society Leif has made huge contributions to our understanding of the biology of the disease. Congrats Leif!
1
7
35
Ken Anderson Basic and translational research award! #IMS2025 Congrats Leif for all you have done in the field of myeloma!!
0
1
4
Happening now abstract session 5 in RM701 #IMS2025
Looking forward to present our new SCOPE-MM score later today at #IMS2025 Abstract Session 5! Result of an awesome collaboration with @KRejeski @YiLinMDPhD and Doris Hansen. Stay tuned!
0
0
1
Looking forward to present our new SCOPE-MM score later today at #IMS2025 Abstract Session 5! Result of an awesome collaboration with @KRejeski @YiLinMDPhD and Doris Hansen. Stay tuned!
#IMS25 | @DavidCdSMD shares his study on the development and validation of the SCOPE-MM score: a pre-apheresis risk model for patients receiving CAR-T. #MMSM #ImmunoOnc #HemOnc @Myeloma_Society
0
3
8
Join @AjayNookaMD and me to share experiences on outpatient practice for #CART #BsAb in #mmsm at noon today, RM714B, #IMS2025: practical management tips, infrastructure considerations, and a peek into roles for remote monitoring, telehealth, AI and ML @MayoCancerCare
It’s always a pleasure to catch up with @YiLinMDPhD! Today she shared insights into outpatient administration of bispecifics and immunotherapy, and absolute lymphocyte count as a biomarker for monitoring safety after cilta-cel. #MMSM #IMS25 @Myeloma_Society
0
1
4
Philippe Moreau at #IMS25 opening lecture: Bob Kyle as early as 1985 proposed possibility of monoclonal antibodies for treatment of myeloma. Incredible. I did not know.
2
14
93
Stop by at lunch session today #IMS2025
For US HCPs at #IMS25, Yi Lin (@YiLinMDPhD) of Mayo Clinic Rochester presents an encore presentation analyzing ALC as a key biomarker for safety monitoring after a BCMA-directed #CART cell therapy. For IMS abstracts, link here: https://t.co/um46vNBhzA.
#mmsm
0
0
8
We are honoring Dr. Bruce Cheson today with the Mayo Clinic Kyle Lifetime Achievement Award. Dr. Cheson helped me greatly in my career. We visited with Dr. Kyle who is 97. Heard remarkable stories about hematology.
7
13
103
Come join us @SocietyofHemOnc #SOHO2025 cellular therapy session NOW starting @RShouval Its definitely not just for the birds!
1
1
21
Great question by @DrJasonWestin #SOHO2025 #lymsm session: when will #AI Machine Learning models be used in real time in the clinic? @jonaspaludo @MayoCancerCare the time is now.
0
5
21